These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 39412611)

  • 1. Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.
    Suoh M; Esmaili S; Eslam M; George J
    Hepatol Int; 2024 Oct; ():. PubMed ID: 39412611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis.
    Liao Y; Wang L; Liu F; Zhou Y; Lin X; Zhao Z; Xu S; Tang D; Jiao Y; Yang L; Yu W; Gao P
    Front Endocrinol (Lausanne); 2023; 14():1078149. PubMed ID: 36761200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.
    Kaya E; Yilmaz Y
    J Clin Transl Hepatol; 2022 Apr; 10(2):329-338. PubMed ID: 35528971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis.
    Li Y; Zhou Y; Wang L; Lin X; Mao M; Yin S; Zhu L; Jiao Y; Yu W; Gao P; Yang L
    Front Endocrinol (Lausanne); 2022; 13():990953. PubMed ID: 36329894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
    Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.
    Grabherr F; Grander C; Effenberger M; Schwärzler J; Tilg H
    Ther Adv Endocrinol Metab; 2022; 13():20420188221139101. PubMed ID: 36439029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAFLD: Renovation of clinical practice and disease awareness of fatty liver.
    Kawaguchi T; Tsutsumi T; Nakano D; Torimura T
    Hepatol Res; 2022 May; 52(5):422-432. PubMed ID: 34472683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.
    Fouad Y; Palmer M; Chen M; Regev A; Banerjee R; Myers R; Riccio R; Torstenson R; Younes R; Arora PS; Landgren H; Karsdal MA; Blake M; Shapiro DA; Gruss HJ; Sheikh MY; Attia D; Bollipo S; Smith AD; Freilich B; Gish RG; Schuppan D
    J Clin Transl Hepatol; 2022 Apr; 10(2):374-382. PubMed ID: 35528969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.
    Zhou XD; Cai J; Targher G; Byrne CD; Shapiro MD; Sung KC; Somers VK; Chahal CAA; George J; Chen LL; Zhou Y; Zheng MH;
    Cardiovasc Diabetol; 2022 Dec; 21(1):270. PubMed ID: 36463192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial: The Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: Why the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) Consensus Process is Not Representative.
    Fouad YM; Gomaa A; El Etreby RM; AbdAllah M; Attia D
    Med Sci Monit; 2022 Aug; 28():e938066. PubMed ID: 35993179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrosis Burden of Missed and Added Populations According to the New Definition of Metabolic Dysfunction-Associated Fatty Liver.
    Park H; Yoon EL; Kim M; Kim JH; Cho S; Jun DW; Nah EH
    J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis.
    Virk GS; Vajje J; Virk NK; Mannam R; Rehman W; Ghobriel NG; Mian IU; Usama M
    Cureus; 2023 Aug; 15(8):e44413. PubMed ID: 37791219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
    Méndez-Sánchez N; Díaz-Orozco LE
    Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies.
    Habibullah M; Jemmieh K; Ouda A; Haider MZ; Malki MI; Elzouki AN
    Front Med (Lausanne); 2024; 11():1291501. PubMed ID: 38323033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.